Effect of Hepatic Impairment on the Pharmacokinetics of Levomilnacipran Following a Single Oral Dose of a Levomilnacipran Extended-Release Capsule in Human Participants
Background and Objectives Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor with greater potency for the reuptake inhibition of norepinephrine than of serotonin, approved in the USA for the treatment of major depressive disorder (MDD) in adults. Methods A single-dose, open-label,...
Saved in:
Published in | Clinical drug investigation Vol. 34; no. 5; pp. 351 - 359 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.05.2014
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!